✦ LIBER ✦

PO67 CLINICAL BENEFIT OF ETHINYLESTRADIOL AS A SALVAGE ENDOCRINE THERAPY FOR THE HEAVILY PRETREATED METASTATIC BREAST CANCER

✍ Scribed by Iwase, Hirotaka; Kondo, Naoto; Yamashita, Toshinari; Nakamura, Seigo; Ikeda, Masahiko; Kawasoe, Tero; Horio, Akiyo; Yamamoto-Ibusuki, Mutsuko; Iwata, Hiroji; Yamamoto, Yutaka

Book ID: 122308196
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 53 KB
Volume: 22
Category: Article
ISSN: 0960-9776
DOI: 10.1016/S0960-9776(13)70081-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination of trastuzumab and gemcitabi

Combination of trastuzumab and gemcitabine as salvage therapy in heavily pretreated patients with metastatic breast cancer

✍ R. Bartsch; C. Wenzel; U. Pluschnig; G. Altorjai; P. Dubsky; R. Scheurer; A. Rot 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Extending the Clinical Benefit of Endocr

Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor–Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action

✍ Glück, Stefan 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 670 KB

Ki67 expression in the primary tumor pre

Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer

✍ Y. Delpech, Y. Wu, K. R. Hess, L. Hsu, M. Ayers, R. Natowicz, C. Coutant, R. Rou 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 357 KB

5019 Pegylated liposomal doxorubicin and

5019 Pegylated liposomal doxorubicin and Bevacizumab as first-line therapy for locallyrecurrent or metastatic breast cancer – a multicenter, single-arm phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)

✍ C. Rochlitz; R. von Moos; M. Mannhart-Harms; R. Winterhalder; D. Rauch; A. Mülle 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

5072 Independent central review of clini

5072 Independent central review of clinical benefit rates in FIRST: a Phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor positive advanced breast cancer

✍ J.P.O. Lindemann; J.F.R. Robertson; M.J. Ellis; Y. Menu; E.J. Macpherson; D.D.C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

First results of a randomized phase III

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

✍ R Paridaens; P Therasse; L Dirix; L Beex; M.J Piccart; D Cameron; T Cufer; K Roo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB